Loading
Cells that receive only a small amount of a drug survive and adapt. Measuring where inside a tumour the drug actually reaches would show where resistance is being bred.
Sub-therapeutic exposure regions, created by poor perfusion, high interstitial pressure and dense stroma, are where selection for resistance is strongest. Imaging mass spectrometry on resected specimens, microdose PET with labelled analogues and intratumoural microdialysis can map drug concentration spatially. Linking these maps to regional clonal composition would show whether resistant clones arise preferentially in low-exposure zones.
Shares Proteomics & phosphoproteomics, Single-cell & spatial profiling.
Shares Tumour heterogeneity and clonal evolution, Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Tumour heterogeneity and clonal evolution, Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Tumour heterogeneity and clonal evolution, Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Wrong doses, Drug resistance (primary and acquired), Acquired resistance to every therapy.